The US Food and Drug Administration (FDA) has granted regulatory clearance to 4DMedical to market its four-dimensional lung imaging process XV Technology.
The technology is a software-as-a-service (SaaS) diagnostic tool available through secure cloud subscription. It can automatically analyse any functional lung impairment from a single X-ray.
4DMedical founder and CEO Andreas Fouras said: “Our XV Technology is a valuable new respiratory diagnostic tool.
“It provides critical information about the functional and structural state of a patient’s lungs in the treatment of illnesses such as Covid-19, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer.
“FDA clearance means we can fast-track our ‘go-to-market’ strategy to ensure hospitals and doctors in the United States have almost immediate access to our XV Technology Ventilation Reports.”
XV Technology can be deployed immediately, using the existing hospital and clinical infrastructure with no capital expenditure or training required, the company noted.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The process requires imaging departments to electronically send an X-ray, which is taken using existing fluoroscopy equipment, to 4DMedical.
4DMedical software identifies and quantifies any functional impairment by rapidly and automatically analysing and applying its proprietary algorithms to the X-ray.
Within three hours, the software provides a ventilation report to the hospital, enabling clinicians to choose the most effective treatment and allocate hospital resources.
The company noted that its ventilation reports can deliver quantitative support for Covid-19 diagnosis and follow up examinations for patients with or recovering from Covid-19.
However, XV Technology is not intended to replace molecular tests as the primary diagnosis method for Covid-19.
XV Technology supported by 15 years of preclinical and clinical trials and existing collaborations with hospitals across the world.
Australian government’s Medical Research Future Fund (MRFF) Frontier Health and Medical Research Programme has validated the technology through an extensive vetting process.